↓ Skip to main content

Renal sympathetic denervation versus antiarrhythmic drugs for drug-resistant hypertension and symptomatic atrial fibrillation (RSDforAF) trial: study protocol for a randomized controlled trial

Overview of attention for article published in Trials, January 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Renal sympathetic denervation versus antiarrhythmic drugs for drug-resistant hypertension and symptomatic atrial fibrillation (RSDforAF) trial: study protocol for a randomized controlled trial
Published in
Trials, January 2013
DOI 10.1186/1745-6215-14-168
Pubmed ID
Authors

Min Qiu, Yuehui Yin, Qijun Shan

Abstract

BACKGROUND: Recently, catheter-based renal sympathetic denervation (RSD) has been verified to be safely used to substantially reduce the levels of blood pressure, left ventricular hypertrophy, sleep apnea severity and norepinephrine spillover, and improve glucose tolerance. All these pathological changes are recognized as independent risk factors for the development and recurrence of atrial fibrillation (AF). A randomized, single-blind, parallel-control, multicenter clinical trial is being conducted to compare RSD with antiarrhythmic drugs (AAD) in patients with drug-resistant hypertension and symptomatic AF (RSDforAF trial).Methods/design: Patients with drug-resistant hypertension and symptomatic AF will be randomized to RSD and the drug treatment groups. Patients will be followed for 12 months until study closure. Up to 200 patients may be enrolled in six medical centers in China. The primary objective is to study the effects of RSD on AF burden and blood pressure in patients with hypertension and symptomatic AF. DISCUSSION: RSDforAF trial will test the hypothesis that RSD is superior to AAD in reducing AF burden and blood pressure in patients with drug-resistant hypertension and symptomatic AF.Trial registration: The trial is registered at www.clinicaltrials.gov, registry number: NCT01713270.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 60 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 25%
Researcher 9 15%
Student > Postgraduate 7 11%
Student > Bachelor 6 10%
Other 6 10%
Other 9 15%
Unknown 9 15%
Readers by discipline Count As %
Medicine and Dentistry 37 61%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Agricultural and Biological Sciences 3 5%
Economics, Econometrics and Finance 2 3%
Biochemistry, Genetics and Molecular Biology 2 3%
Other 4 7%
Unknown 9 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2013.
All research outputs
#2,016,247
of 3,629,356 outputs
Outputs from Trials
#687
of 1,110 outputs
Outputs of similar age
#44,823
of 85,209 outputs
Outputs of similar age from Trials
#47
of 68 outputs
Altmetric has tracked 3,629,356 research outputs across all sources so far. This one is in the 25th percentile – i.e., 25% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,110 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 85,209 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.